Spyre Therapeutics stock rises after Deutsche Bank initiates coverage, sets $43 PT
PositiveFinancial Markets

Spyre Therapeutics saw a significant boost in its stock price after Deutsche Bank initiated coverage with a price target of $43. This positive outlook from a major financial institution highlights the company's potential for growth and investor interest, making it a noteworthy development in the biotech sector.
— Curated by the World Pulse Now AI Editorial System